Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast Cancer.

Autor: Gemma C; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Lai CF; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Singh AK; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Belfiore A; Pathology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.; School of Medicine, University of Milan, Milan, Italy., Portman N; Garvan Institute of Medical Research, Darlinghurst, Australia., Milioli HZ; Garvan Institute of Medical Research, Darlinghurst, Australia., Periyasamy M; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Raafat S; Division of Cancer and Stem Cells, Nottingham Breast Cancer Research Centre, University of Nottingham Biodiscovery Institute, University Park, Nottingham, United Kingdom.; Department of Histopathology, Nottingham University Hospital NHS Trust, City Hospital Campus, Nottingham, United Kingdom., Nicholls AJ; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Davies CM; Department of Surgery and Cancer, ECMC Imperial College, Imperial College London, Hammersmith Campus, London, United Kingdom., Patel NR; Department of Surgery and Cancer, ECMC Imperial College, Imperial College London, Hammersmith Campus, London, United Kingdom., Simmons GM; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Fan H; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Nguyen VTM; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Magnani L; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Rakha E; Division of Cancer and Stem Cells, Nottingham Breast Cancer Research Centre, University of Nottingham Biodiscovery Institute, University Park, Nottingham, United Kingdom.; Department of Histopathology, Nottingham University Hospital NHS Trust, City Hospital Campus, Nottingham, United Kingdom., Martin LA; Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London, United Kingdom., Lim E; Garvan Institute of Medical Research, Darlinghurst, Australia.; St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales Sydney, Sydney, Australia., Coombes RC; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Pruneri G; Pathology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.; School of Medicine, University of Milan, Milan, Italy., Buluwela L; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Ali S; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom.

Publikováno v: Cancer research [Cancer Res] 2024 Dec 16; Vol. 84 (24), pp. 4283-4297.

AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution.

Autor: Schade AE; Division of Genetics, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Perurena N; Division of Genetics, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Yang Y; Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA.; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Rodriguez CL; Division of Genetics, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Krishnan A; Division of Genetics, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Gardner A; Division of Genetics, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Loi P; Division of Genetics, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Xu Y; Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA.; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Nguyen VTM; Division of Cancer Biology, Institute of Cancer Research, London, UK., Mastellone GM; Division of Genetics, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Pilla NF; Division of Genetics, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Watanabe M; Division of Genetics, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Ota K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Davis RA; Division of Genetics, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Mattioli K; Division of Genetics, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Xiang D; Division of Genetics, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Zoeller JJ; Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA.; Department of Cell Biology, Harvard Medical School, Boston, MA, USA., Lin JR; Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA.; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Morganti S; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Garrido-Castro AC; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Tolaney SM; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Li Z; Division of Genetics, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sorger PK; Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA.; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Systems Biology, Harvard Medical School, Boston, MA, USA., Helin K; Division of Cancer Biology, Institute of Cancer Research, London, UK., Santagata S; Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA.; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Department of Systems Biology, Harvard Medical School, Boston, MA, USA., Knott SRV; Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA.; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Cichowski K; Division of Genetics, Brigham and Women's Hospital, Boston, MA, USA. kcichowski@rics.bwh.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. kcichowski@rics.bwh.harvard.edu.; Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA. kcichowski@rics.bwh.harvard.edu.

Publikováno v: Nature [Nature] 2024 Nov; Vol. 635 (8039), pp. 755-763. Date of Electronic Publication: 2024 Oct 09.

Author Correction: Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion.

Autor: Nguyen VTM; Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK., Barozzi I; IFOM-IEO Campus, European Institute of Oncology, Milan, 20139, Italy., Faronato M; Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK., Lombardo Y; Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK., Steel JH; Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK., Patel N; Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK., Darbre P; School of Biological Science, University of Reading, Reading, RG6 6LA, UK., Castellano L; Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK., Győrffy B; MTATTK Lendület Cancer Biomarker Research Group, 2nd Department of Pediatrics, Semmelweis University, Budapest, H-1117, Hungary.; MTA-SE Pediatrics and Nephrology Research Group, 2nd Department of Pediatrics, Semmelweis University, Budapest, H-1117, Hungary., Woodley L; ECMC, Charing Cross Hospital, London, W120nn, UK., Rodriguez-Meira A; Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK., Patten DK; Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK., Vircillo V; Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende (CS), 87036, Italy., Periyasamy M; Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK., Ali S; Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK., Frige G; IFOM-IEO Campus, European Institute of Oncology, Milan, 20139, Italy., Minucci S; IFOM-IEO Campus, European Institute of Oncology, Milan, 20139, Italy., Coombes RC; Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK., Magnani L; Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK. l.magnani@imperial.ac.uk.

Publikováno v: Nature communications [Nat Commun] 2019 Aug 06; Vol. 10 (1), pp. 3505. Date of Electronic Publication: 2019 Aug 06.

Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.

Autor: Harrod A; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Fulton J; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Nguyen VTM; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Periyasamy M; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Ramos-Garcia L; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Lai CF; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Metodieva G; School of Biological Sciences, University of Essex, Wivenhoe Park, Colchester, UK., de Giorgio A; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Williams RL; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Santos DB; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Gomez PJ; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Lin ML; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Metodiev MV; School of Biological Sciences, University of Essex, Wivenhoe Park, Colchester, UK., Stebbing J; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Castellano L; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Magnani L; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Coombes RC; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Buluwela L; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Ali S; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.

Publikováno v: Oncogene [Oncogene] 2017 Apr 20; Vol. 36 (16), pp. 2286-2296. Date of Electronic Publication: 2016 Oct 17.